凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
卫信康(603676)公告正文

卫信康:2018年第三季度报告

公告日期 2018-10-26
股票简称:卫信康 股票代码:603676
                       2018 年第三季度报告



公司代码:603676                             公司简称:卫信康




              西藏卫信康医药股份有限公司
                  2018 年第三季度报告




                             1 / 19
                                 2018 年第三季度报告




                                    目录
一、   重要提示.................................................................. 3
二、   公司基本情况 .............................................................. 3
三、   重要事项.................................................................. 5
四、   附录...................................................................... 7




                                       2 / 19
                                   2018 年第三季度报告




一、 重要提示


1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,

    不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。



1.2 公司全体董事出席董事会审议季度报告。



1.3 公司负责人张勇、主管会计工作负责人熊晓萍及会计机构负责人(会计主管人员)熊晓萍保

    证季度报告中财务报表的真实、准确、完整。



1.4 本公司第三季度报告未经审计。




二、 公司基本情况


2.1 主要财务数据
                                                                  单位:元 币种:人民币
                                                                     本报告期末比上年度末
                      本报告期末                  上年度末
                                                                           增减(%)
总资产              1,101,867,101.59              1,016,628,498.94                   8.38
归属于上市公司股      888,633,479.48               858,043,508.74                    3.57
东的净资产
                    年初至报告期末         上年初至上年报告期末
                                                                      比上年同期增减(%)
                      (1-9 月)                 (1-9 月)
经营活动产生的现       79,887,156.97                37,811,798.66                  111.28
金流量净额
                    年初至报告期末         上年初至上年报告期末        比上年同期增减
                      (1-9 月)                 (1-9 月)                (%)
营业收入              476,906,154.52               280,835,953.76                   69.82
归属于上市公司股       64,393,155.72                77,158,400.37                  -16.54
东的净利润
归属于上市公司股       44,391,119.03                62,246,915.59                  -28.69
东的扣除非经常性
损益的净利润

                                         3 / 19
                                         2018 年第三季度报告



加权平均净资产收                     7.23                               13.68        减少 6.45 个百分点
益率(%)
基本每股收益(元/                    0.15                                0.21                      -28.57
股)
稀释每股收益(元/                    0.15                                0.21                      -28.57
股)


非经常性损益项目和金额
√适用 □不适用
                                                                       单位:元 币种:人民币
                                            本期金额       年初至报告期末金额     说明
               项目
                                          (7-9 月)          (1-9 月)
非流动资产处置损益                            54,199.97                  146,467.52
计入当期损益的政府补助,但与公            1,163,404.09                3,123,012.28
司正常经营业务密切相关,符合国
家政策规定、按照一定标准定额或
定量持续享受的政府补助除外
委托他人投资或管理资产的损益                 205,868.52               2,323,235.13      理财收益
其他符合非经常性损益定义的损益                                     16,881,975.92
项目
所得税影响额                                -280,115.92            -2,472,654.16
               合计                        1,143,356.66            20,002,036.69



2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
                                                                                              单位:股
股东总数(户)                                                                                     29,730
                                     前十名股东持股情况
                                            持有有限售            质押或冻结情况
  股东名称       期末持股数       比例
                                            条件股份数                                       股东性质
  (全称)           量           (%)                          股份状态          数量
                                                量
西藏卫信康投     205,248,960      48.52     205,248,960                         3,200,000   境内非国有
资管理有限公                                                     质押                           法人

张勇              53,402,400      12.62      53,402,400          无                         境内自然人
西藏京卫信康      51,312,240      12.13      51,312,240                                        其他
投资管理合伙
                                                                 无
企业(有限合
伙)
钟丽娟            36,000,000       8.51      36,000,000          质押       15,000,000      境内自然人
钟丽芳                7,200,000    1.70       7,200,000          无                         境内自然人
张宏                  3,175,920    0.75       3,175,920          无                         境内自然人
刘烽                  3,175,920    0.75                          无                         境内自然人

                                               4 / 19
                                       2018 年第三季度报告



温小泉             484,560          0.11                       无                       境内自然人
金卫国             344,700          0.08                       无                       境内自然人
杜海燕             324,800          0.08                       无                       境内自然人
                                  前十名无限售条件股东持股情况
股东名称                      持有无限售条件流通股的数                     股份种类及数量
                                        量                               种类             数量
刘烽                                              3,175,920         人民币普通股          3,175,920
温小泉                                              484,560         人民币普通股               484,560
金卫国                                              344,700         人民币普通股               344,700
杜海燕                                              324,800         人民币普通股               324,800
罗华                                                323,700         人民币普通股               323,700
梅林                                                225,900         人民币普通股               225,900
赵秀芳                                              223,000         人民币普通股               223,000
史招山                                              214,665         人民币普通股               214,665
王战叶                                              207,252         人民币普通股               207,252
陈娟                                                183,600         人民币普通股               183,600
上述股东关联关系或一致       张勇、钟丽娟为夫妻关系,张勇、张宏为兄弟关系,钟丽娟、钟丽
行动的说明                   芳为姐妹关系,张勇为西藏卫信康投资管理有限公司、西藏京卫信
                             康投资管理合伙企业(有限合伙)的实际控制人。公司未知悉其他
                             股东之间是否存在关联关系或属于《上市公司收购管理办法》规定
                             的一致行动人。
表决权恢复的优先股股东       无
及持股数量的说明



2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情

       况表
□适用 √不适用



三、 重要事项


3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
√适用 □不适用

                         期末余额             期初余额        变动比率
       报表项目                                                                     变动原因
                   (或本期金额)          (或上期金额)      (%)
预付款项             81,136,937.37           21,674,421.07       274.34    主要系预付货款增加所致
存货                 18,226,603.97           39,063,207.14       -53.34    主要系商品销售所致
在建工程            156,875,062.33           71,310,206.68       119.99    主要系购入房产转入在建工
                                                                           程所致


                                               5 / 19
                                      2018 年第三季度报告



无形资产             23,724,971.60         8,505,381.27      178.94   主要系研发项目开发支出转
                                                                      入无形资产所致
开发支出             21,130,940.08        33,699,050.92      -37.30   主要系研发项目开发支出转
                                                                      入无形资产所致
长期待摊费用          4,530,300.26         2,873,385.79       57.66   主要系研发中心实验室装修
                                                                      增加所致
递延所得税资产        9,195,927.51        14,898,264.81      -38.28   主要系下属子公司亏损转盈
                                                                      利,可弥补亏损减少所致
其他非流动资产       14,949,413.37        56,477,503.94      -73.53   主要系购入房产转入在建工
                                                                      程所致
应付票据及应付账款   140,993,798.91       77,683,923.75       81.50   主要系公司加强产品学术推
                                                                      广及销售终端开发力度所致
预收款项             12,855,834.07        18,653,640.80      -31.08   主要系本期实现销售所致
应付职工薪酬          4,082,437.91         9,048,524.97      -54.88   主要系本年支付上年的年终
                                                                      奖所致
应交税费              3,004,106.18         7,432,907.49      -59.58   主要系购入房产的待抵扣进
                                                                      项税额较大所致
递延收益              4,771,535.84         6,871,480.98      -30.56   主要系本年分摊以前年度收
                                                                      到政府补助所致
递延所得税负债                               122,408.98     -100.00   主要系上年末计提的理财收
                                                                      益相应的所得税已缴纳所致
营业收入             476,906,154.52      280,835,953.76       69.82   主要系受“两票制”政策影
                                                                      响,合作产品技术使用收入、
                                                                      商标/品牌使用收入、市场管
                                                                      理及推广服务收入有较大幅
                                                                      度增长
营业成本             246,727,115.00      113,826,431.73      116.76   主要系受“两票制”政策影
                                                                      响,随本期营业收入增长,合
                                                                      作产品的市场推广服务成本
                                                                      相应增加
销售费用             127,380,136.14       44,732,979.70      184.76   主要系优化产品市场战略布
                                                                      局,加强学术推广投入力度,
                                                                      做好产品专业知识培训,提高
                                                                      产品认知度所致
财务费用             -1,060,395.08        -3,109,148.80      不适用   主要系本期银行存款减少利
                                                                      息减少所致
资产减值损失          1,295,477.36         2,311,350.93      -43.95   主要系应收账款收回坏账损
                                                                      失减少所致
其他收益              2,116,745.14           573,271.98      269.24   主要系本年分摊以前年度收
                                                                      到政府补助所致
投资收益             25,424,610.75         2,996,362.57      748.52   主要系本年出售子公司所致
营业外收入            1,006,267.14        10,983,318.89      -90.84   主要系本年收到的政府补助
                                                                      减少所致

                                            6 / 19
                                             2018 年第三季度报告



经营活动产生的现金          79,887,156.97        37,811,798.66          111.28    主要系营业收入增加所致
流量净额
投资活动产生的现金          104,947,624.27     -328,952,436.99          不适用    主要本年理财减少所致
流量净额
筹资活动产生的现金      -209,327,180.80         239,732,700.46         -187.32    主要系本年支付股利所致
流量净额




3.2 重要事项进展情况及其影响和解决方案的分析说明
□适用 √不适用



3.3 报告期内超期未履行完毕的承诺事项
□适用 √不适用



3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警

    示及原因说明
□适用 √不适用



                                                                                 西藏卫信康医药股份有限
                                                                   公司名称
                                                                                 公司
                                                               法定代表人        张勇
                                                                       日期      2018 年 10 月 25 日




四、 附录


4.1 财务报表
                                    合并资产负债表
                                   2018 年 9 月 30 日
编制单位:西藏卫信康医药股份有限公司

                                                       单位:元 币种:人民币 审计类型:未经审计
                     项目                                   期末余额                      年初余额
流动资产:
  货币资金                                                    83,618,033.22                 75,369,736.38
  结算备付金
  拆出资金

                                                   7 / 19
                                 2018 年第三季度报告



  以公允价值计量且其变动计入当期损
益的金融资产
  衍生金融资产
  应收票据及应收账款                            146,140,845.85       148,703,157.64
  其中:应收票据                                 13,141,873.08         5,580,260.40
         应收账款                               132,998,972.77       143,122,897.24
  预付款项                                       81,136,937.37        21,674,421.07
  应收保费
  应收分保账款
  应收分保合同准备金
  其他应收款                                      2,034,537.98         1,863,063.04
  其中:应收利息
         应收股利
  买入返售金融资产
  存货                                           18,226,603.97        39,063,207.14
  持有待售资产
  一年内到期的非流动资产
  其他流动资产                                  404,739,869.69       390,558,206.46
   流动资产合计                                 735,896,828.08       677,231,791.73
非流动资产:
  发放贷款和垫款
  可供出售金融资产                                9,000,000.00
  持有至到期投资
  长期应收款
  长期股权投资
  投资性房地产
  固定资产                                      126,348,576.79       151,417,832.23
  在建工程                                      156,875,062.33        71,310,206.68
  生产性生物资产
  油气资产
  无形资产                                       23,724,971.60         8,505,381.27
  开发支出                                       21,130,940.08        33,699,050.92
  商誉                                                 215,081.57        215,081.57
  长期待摊费用                                    4,530,300.26         2,873,385.79
  递延所得税资产                                 9,195,927.51         14,898,264.81
  其他非流动资产                                 14,949,413.37        56,477,503.94
   非流动资产合计                               365,970,273.51       339,396,707.21
     资产总计                               1,101,867,101.59        1,016,628,498.94
流动负债:
  短期借款
  向中央银行借款
  吸收存款及同业存放
                                       8 / 19
                                 2018 年第三季度报告



  拆入资金
  以公允价值计量且其变动计入当期损
益的金融负债
  衍生金融负债
  应付票据及应付账款                            140,993,798.91    77,683,923.75
  预收款项                                       12,855,834.07    18,653,640.80
  卖出回购金融资产款
  应付手续费及佣金
  应付职工薪酬                                    4,082,437.91     9,048,524.97
  应交税费                                        3,004,106.18     7,432,907.49
  其他应付款                                    47,525,909.20     38,772,103.23
  其中:应付利息
       应付股利
  应付分保账款
  保险合同准备金
  代理买卖证券款
  代理承销证券款
  持有待售负债
  一年内到期的非流动负债
  其他流动负债
   流动负债合计                                 208,462,086.27   151,591,100.24
非流动负债:
  长期借款
  应付债券
  其中:优先股
       永续债
  长期应付款
  长期应付职工薪酬
  预计负债
  递延收益                                        4,771,535.84     6,871,480.98
  递延所得税负债                                                    122,408.98
  其他非流动负债
   非流动负债合计                                 4,771,535.84     6,993,889.96
     负债合计                                   213,233,622.11   158,584,990.20
所有者权益(或股东权益)
  实收资本(或股本)                            423,000,000.00   423,000,000.00
  其他权益工具
  其中:优先股
       永续债
  资本公积                                      256,832,684.47   256,832,684.47
  减:库存股
  其他综合收益
                                       9 / 19
                                   2018 年第三季度报告



  专项储备
  盈余公积                                          29,162,540.09           29,183,958.42
  一般风险准备
  未分配利润                                       179,638,254.92          149,026,865.85
  归属于母公司所有者权益合计                       888,633,479.48          858,043,508.74
  少数股东权益
    所有者权益(或股东权益)合计                   888,633,479.48          858,043,508.74
       负债和所有者权益(或股东权益)         1,101,867,101.59           1,016,628,498.94
总计


法定代表人:张勇        主管会计工作负责人:熊晓萍            会计机构负责人:熊晓萍



                                   母公司资产负债表
                                   2018 年 9 月 30 日
编制单位:西藏卫信康医药股份有限公司
                                               单位:元 币种:人民币 审计类型:未经审计
                 项目                          期末余额                  年初余额
流动资产:
  货币资金                                          29,264,353.68           32,818,935.22
  以公允价值计量且其变动计入当期损
益的金融资产
  衍生金融资产
  应收票据及应收账款
  其中:应收票据
         应收账款
  预付款项                                            349,034.61
  其他应收款                                        78,625,279.50           86,202,495.12
  其中:应收利息
         应收股利
  存货
  持有待售资产
  一年内到期的非流动资产
  其他流动资产                                     151,583,091.52          150,025,945.32
    流动资产合计                                   259,821,759.31          269,047,375.66
非流动资产:
  可供出售金融资产                                   9,000,000.00
  持有至到期投资
  长期应收款
  长期股权投资                                     547,307,123.11          566,267,123.11
  投资性房地产
  固定资产                                           1,316,091.89            2,054,413.91

                                         10 / 19
                                 2018 年第三季度报告



  在建工程
  生产性生物资产
  油气资产
  无形资产
  开发支出
  商誉
  长期待摊费用
  递延所得税资产                                        177.03            58.00
  其他非流动资产
   非流动资产合计                                557,623,392.03   568,321,595.02
     资产总计                                    817,445,151.34   837,368,970.68
流动负债:
  短期借款
  以公允价值计量且其变动计入当期损
益的金融负债
  衍生金融负债
  应付票据及应付账款
  预收款项
  应付职工薪酬                                      238,380.29       396,065.00
  应交税费                                          418,887.20       536,554.90
  其他应付款                                           6,327.94
  其中:应付利息
         应付股利
  持有待售负债
  一年内到期的非流动负债
  其他流动负债
   流动负债合计                                     663,595.43       932,619.90
非流动负债:
  长期借款
  应付债券
  其中:优先股
         永续债
  长期应付款
  长期应付职工薪酬
  预计负债
  递延收益
  递延所得税负债                                                      81,511.11
  其他非流动负债
   非流动负债合计                                                     81,511.11
     负债合计                                       663,595.43      1,014,131.01
所有者权益(或股东权益)
  实收资本(或股本)                             423,000,000.00   423,000,000.00
                                       11 / 19
                                       2018 年第三季度报告



  其他权益工具
  其中:优先股
          永续债
  资本公积                                             284,522,129.28          284,522,129.28
  减:库存股
  其他综合收益
  专项储备
  盈余公积                                              29,183,958.42           29,183,958.42
  未分配利润                                            80,075,468.21           99,648,751.97
       所有者权益(或股东权益)合计                    816,781,555.91          836,354,839.67
        负债和所有者权益(或股东权益)                 817,445,151.34          837,368,970.68
总计


法定代表人:张勇           主管会计工作负责人:熊晓萍               会计机构负责人:熊晓萍

                                          合并利润表
                                        2018 年 1—9 月
编制单位:西藏卫信康医药股份有限公司
                                                 单位:元 币种:人民币 审计类型:未经审计
                                                              年初至报告期     上年年初至报告
                          本期金额           上期金额
          项目                                                期末金额 (1-9   期期末金额(1-9
                          (7-9 月)         (7-9 月)
                                                                  月)               月)
一、营业总收入          176,976,774.11     92,046,020.86      476,906,154.52   280,835,953.76
其中:营业收入          176,976,774.11     92,046,020.86      476,906,154.52   280,835,953.76
        利息收入
        已赚保费
        手续费及佣金
收入
二、营业总成本          171,253,385.42     79,867,020.75      431,277,875.72   209,371,060.08
其中:营业成本           80,708,246.33     51,152,281.69      246,727,115.00   113,826,431.73
        利息支出
        手续费及佣金
支出
        退保金
        赔付支出净额
      提取保险合同
准备金净额
        保单红利支出
        分保费用
        税金及附加        1,860,662.31         913,707.99       4,770,931.03     3,742,318.78
                         67,488,150.13     10,087,260.91      127,380,136.14   44,732,979.70
        销售费用


                                             12 / 19
                                    2018 年第三季度报告



      管理费用           13,380,285.17   10,673,635.96    35,350,751.64   29,448,926.42
      研发费用            6,874,083.43    6,116,070.99    16,813,859.63   18,418,201.32
      财务费用             -488,348.26     -202,348.25    -1,060,395.08   -3,109,148.80
      其中:利息费用
             利息收        -476,776.00     -219,583.74    -1,098,679.40   -3,158,084.71

      资产减值损失        1,430,306.31    1,126,411.46     1,295,477.36    2,311,350.93
  加:其他收益             769,495.87       254,012.11     2,116,745.14     573,271.98
      投资收益(损失      2,745,394.15    1,458,213.41    25,424,610.75    2,996,362.57
以“-”号填列)
      其中:对联营企
业和合营企业的投资
收益
      公允价值变动
收益(损失以“-”号
填列)
      资产处置收益                                          146,467.52
(损失以“-”号填列)
      汇兑收益(损失
以“-”号填列)
三、营业利润(亏损以      9,238,278.71   13,891,225.63    73,316,102.21   75,034,528.23
“-”号填列)
  加:营业外收入           393,908.22       382,109.99     1,006,267.14   10,983,318.89
  减:营业外支出                            102,572.51      104,750.00      136,126.98
四、利润总额(亏损总      9,632,186.93   14,170,763.11    74,217,619.35   85,881,720.14
额以“-”号填列)
  减:所得税费用          1,795,363.66    1,780,402.95     9,824,463.63    8,723,319.77
五、净利润(净亏损以      7,836,823.27   12,390,360.16    64,393,155.72   77,158,400.37
“-”号填列)
  (一)按经营持续性
分类
      1.持续经营净        7,836,823.27   12,390,360.16    64,393,155.72   77,158,400.37
利润(净亏损以“-”
号填列)
      2.终止经营净
利润(净亏损以“-”
号填列)
  (二)按所有权归属
分类
      1.归属于母公        7,836,823.27   12,390,360.16    64,393,155.72   77,158,400.37
司所有者的净利润
     2.少数股东损

                                          13 / 19
                                 2018 年第三季度报告



六、其他综合收益的税
后净额
  归属母公司所有者
的其他综合收益的税
后净额
    (一)不能重分类
进损益的其他综合收

      1.重新计量设
定受益计划变动额
      2.权益法下不
能转损益的其他综合
收益
    (二)将重分类进
损益的其他综合收益
      1.权益法下可
转损益的其他综合收

      2.可供出售金
融资产公允价值变动
损益
      3.持有至到期
投资重分类为可供出
售金融资产损益
      4.现金流量套
期损益的有效部分
      5.外币财务报
表折算差额
  归属于少数股东的
其他综合收益的税后
净额
七、综合收益总额       7,836,823.27   12,390,360.16     64,393,155.72   77,158,400.37
  归属于母公司所有     7,836,823.27   12,390,360.16     64,393,155.72   77,158,400.37
者的综合收益总额
  归属于少数股东的
综合收益总额
八、每股收益:
 (一)基本每股收益           0.02               0.03           0.15            0.21
(元/股)
 (二)稀释每股收益           0.02               0.03           0.15            0.21
(元/股)



                                       14 / 19
                                    2018 年第三季度报告



本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0 元,上期被合并方实现的
净利润为:0 元。
法定代表人:张勇    主管会计工作负责人:熊晓萍        会计机构负责人:熊晓萍



                                      母公司利润表
                                     2018 年 1—9 月
编制单位:西藏卫信康医药股份有限公司
                                                  单位:元币种:人民币审计类型:未经审计
                                                          年初至报告期期 上年年初至报告
                          本期金额          上期金额
        项目                                                  末金额        期期末金额
                          (7-9 月)      (7-9 月)
                                                            (1-9 月)      (1-9 月)
一、营业收入
  减:营业成本
      税金及附加
      销售费用                2,494.17                        2,494.17       163,600.00
      管理费用             1,174,893.13     540,234.70     2,316,179.44    1,309,175.40
      研发费用              231,274.44      231,274.44      693,823.32       693,823.32
      财务费用              -34,380.66     -122,287.71      -155,751.98     -127,489.07
      其中:利息费用
               利息收入      -3,699.57     -123,928.48     -127,321.34     -130,821.04
      资产减值损失          -33,181.02                        1,322.52          151.14
  加:其他收益
      投资收益(损失以     1,240,548.70     273,026.97    18,535,901.16      519,180.63
“-”号填列)
      其中:对联营企业
和合营企业的投资收益
      公允价值变动收
益(损失以“-”号填列)
      资产处置收益(损
失以“-”号填列)
二、营业利润(亏损以        -100,551.36    -376,194.46    15,677,833.69   -1,520,080.16
“-”号填列)
  加:营业外收入                     -                                     1,793,929.17
  减:营业外支出
三、利润总额(亏损总额      -100,551.36    -376,194.46    15,677,833.69      273,849.01
以“-”号填列)
    减:所得税费用           -8,946.28      -33,857.50     1,411,103.85       24,646.41
四、净利润(净亏损以        -91,605.08     -342,336.96    14,266,729.84      249,202.60
“-”号填列)
  (一)持续经营净利润      -91,605.08     -342,336.96    14,266,729.84      249,202.60
(净亏损以“-”号填列)
  (二)终止经营净利润
                                          15 / 19
                                   2018 年第三季度报告



(净亏损以“-”号填列)
五、其他综合收益的税后
净额
  (一)不能重分类进损
益的其他综合收益
    1.重新计量设定受
益计划变动额
    2.权益法下不能转损
益的其他综合收益
  (二)将重分类进损益
的其他综合收益
    1.权益法下可转损
益的其他综合收益
    2.可供出售金融资
产公允价值变动损益
    3.持有至到期投资
重分类为可供出售金融
资产损益
    4.现金流量套期损
益的有效部分
    5.外币财务报表折
算差额
六、综合收益总额            -91,605.08    -342,336.96      14,266,729.84      249,202.60
七、每股收益:
    (一)基本每股收益
(元/股)
    (二)稀释每股收益
(元/股)

法定代表人:张勇       主管会计工作负责人:熊晓萍         会计机构负责人:熊晓萍




                                  合并现金流量表
                                    2018 年 1—9 月
编制单位:西藏卫信康医药股份有限公司
                                                单位:元币种:人民币审计类型:未经审计
                   项目                     年初至报告期期末        上年年初至报告期期末
                                              金额(1-9月)             金额(1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                     515,407,893.96          228,287,114.58
  客户存款和同业存放款项净增加额
  向中央银行借款净增加额

                                         16 / 19
                                   2018 年第三季度报告



  向其他金融机构拆入资金净增加额
  收到原保险合同保费取得的现金
  收到再保险业务现金净额
  保户储金及投资款净增加额
  处置以公允价值计量且其变动计入当期损
益的金融资产净增加额
  收取利息、手续费及佣金的现金
  拆入资金净增加额
  回购业务资金净增加额
  收到的税费返还
  收到其他与经营活动有关的现金                      83,443,379.09      15,367,222.47
   经营活动现金流入小计                            598,851,273.05     243,654,337.05
  购买商品、接受劳务支付的现金                     185,695,111.01      66,766,616.04
  客户贷款及垫款净增加额
  存放中央银行和同业款项净增加额
  支付原保险合同赔付款项的现金
  支付利息、手续费及佣金的现金
  支付保单红利的现金
  支付给职工以及为职工支付的现金                    49,812,074.52      46,851,273.56
  支付的各项税费                                    41,021,948.31      36,607,353.37
  支付其他与经营活动有关的现金                     242,434,982.24      55,617,295.42
   经营活动现金流出小计                            518,964,116.08     205,842,538.39
      经营活动产生的现金流量净额                    79,887,156.97      37,811,798.66
二、投资活动产生的现金流量:
  收回投资收到的现金                               553,950,291.67      50,000,000.00
  取得投资收益收到的现金                             9,509,350.11       3,053,986.92
  处置固定资产、无形资产和其他长期资产                   191,000.00
收回的现金净额
  处置子公司及其他营业单位收到的现金净              35,304,200.00

  收到其他与投资活动有关的现金                     619,910,000.00     501,468,178.37
   投资活动现金流入小计                        1,218,864,841.78       554,522,165.29
  购建固定资产、无形资产和其他长期资产              59,377,217.51      12,414,602.28
支付的现金
  投资支付的现金                                   630,100,000.00
  质押贷款净增加额
  取得子公司及其他营业单位支付的现金净               9,000,000.00

  支付其他与投资活动有关的现金                     591,500,000.00     871,060,000.00
   投资活动现金流出小计                        1,290,177,217.51       883,474,602.28
      投资活动产生的现金流量净额                   -71,312,375.73     -328,952,436.99
三、筹资活动产生的现金流量:

                                         17 / 19
                                   2018 年第三季度报告



  吸收投资收到的现金                                                       258,529,900.00
  其中:子公司吸收少数股东投资收到的现

  取得借款收到的现金
  发行债券收到的现金
  收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                                   258,529,900.00
  偿还债务支付的现金
  分配股利、利润或偿付利息支付的现金                33,067,180.80            3,452,105.63
  其中:子公司支付给少数股东的股利、利

  支付其他与筹资活动有关的现金                                              15,345,093.91
    筹资活动现金流出小计                            33,067,180.80           18,797,199.54
      筹资活动产生的现金流量净额                   -33,067,180.80          239,732,700.46
四、汇率变动对现金及现金等价物的影响
五、现金及现金等价物净增加额                       -24,492,399.56          -51,407,937.87
  加:期初现金及现金等价物余额                     108,110,432.78           89,274,242.07
六、期末现金及现金等价物余额                        83,618,033.22           37,866,304.20

法定代表人:张勇          主管会计工作负责人:熊晓萍         会计机构负责人:熊晓萍



                                  母公司现金流量表
                                    2018 年 1—9 月
编制单位:西藏卫信康医药股份有限公司
                                                单位:元币种:人民币审计类型:未经审计
                   项目                    年初至报告期期末金       上年年初至报告期期末
                                                   额                   金额(1-9 月)
                                               (1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金
  收到的税费返还
  收到其他与经营活动有关的现金                      56,569,105.45            4,424,326.14
    经营活动现金流入小计                            56,569,105.45            4,424,326.14
  购买商品、接受劳务支付的现金
  支付给职工以及为职工支付的现金                     3,292,194.90            1,113,494.05
  支付的各项税费                                     1,654,501.65             538,992.99
  支付其他与经营活动有关的现金                      49,071,681.46            1,238,348.93
    经营活动现金流出小计                            54,018,378.01            2,890,835.97
  经营活动产生的现金流量净额                         2,550,727.44            1,533,490.17
二、投资活动产生的现金流量:
  收回投资收到的现金                               508,300,291.67

                                         18 / 19
                                   2018 年第三季度报告



  取得投资收益收到的现金                             4,137,380.15             519,180.63
  处置固定资产、无形资产和其他长期资产
收回的现金净额
  处置子公司及其他营业单位收到的现金净              35,304,200.00

  收到其他与投资活动有关的现金                      29,560,000.00         124,000,000.00
   投资活动现金流入小计                            577,301,871.82         124,519,180.63
  购建固定资产、无形资产和其他长期资产
支付的现金
  投资支付的现金                                   487,840,000.00         176,000,000.00
  取得子公司及其他营业单位支付的现金净               9,000,000.00

  支付其他与投资活动有关的现金                      53,500,000.00         241,560,000.00
   投资活动现金流出小计                            550,340,000.00         417,560,000.00
      投资活动产生的现金流量净额                    26,961,871.82        -293,040,819.37
三、筹资活动产生的现金流量:
  吸收投资收到的现金                                                      308,529,900.00
  取得借款收到的现金
  发行债券收到的现金
  收到其他与筹资活动有关的现金
   筹资活动现金流入小计                                                   308,529,900.00
  偿还债务支付的现金
  分配股利、利润或偿付利息支付的现金                33,067,180.80           3,452,105.63
  支付其他与筹资活动有关的现金                                             14,595,093.91
   筹资活动现金流出小计                             33,067,180.80          18,047,199.54
      筹资活动产生的现金流量净额                   -33,067,180.80         290,482,700.46
四、汇率变动对现金及现金等价物的影响
五、现金及现金等价物净增加额                        -3,554,581.54          -1,024,628.74
  加:期初现金及现金等价物余额                      32,818,935.22           6,292,704.13
六、期末现金及现金等价物余额                        29,264,353.68           5,268,075.39

法定代表人:张勇       主管会计工作负责人:熊晓萍          会计机构负责人:熊晓萍



4.2 审计报告
□适用 √不适用




                                         19 / 19
数据加载中...
prevnext
手机查看股票